PP_1170x120_10-25-21

t ertapenem injection

Aurobindo receives FDA approval for ertapenem injection

Aurobindo receives FDA approval for ertapenem injection

EAST WINDSOR, N.J. — Aurobindo Pharma announced that the company has received final approval from the U.S. Food & Drug Administration to manufacture and market ertapenem injection 1 g/vial. Aurobindo’s ertapenem injection is a generic equivalent of Merck Sharp & Dohme Corp’s Invanz Injection. The product will be launched in July 2018. The approved product

Adheris Health